Official Title
A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
Phase
N/ALead Sponsor
Kunming Medical UniversityStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Depression Secondary to Other Disease ...Intervention/Treatment
escitalopram ...Study Participants
200The purpose of this study is:
to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
to find possible predispose to MDD
to explore the DNA methylation status in depression;
to explore the pathology of depression
to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
to explore the effect of gene-environment interaction on the epigenetic regulation of the depression
A,1: Escitalopram, oral, 20 mg/day, 8 weeks
Inclusion Criteria: DSM-IV Major Depression or Dysthymia Age 18-65 Physically healthy Drug-free Exclusion Criteria: Body metal (e.g., wire stitches, screws in bones, stainless steel hips) History of Psychosis or Epilepsy Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol) Bipolar I Need for wash-out from effective treatment in order to participate Pregnant High suicide risk Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants